Edition:
United Kingdom

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

1.20USD
18 Jan 2018
Change (% chg)

$-0.04 (-3.23%)
Prev Close
$1.24
Open
$1.21
Day's High
$1.23
Day's Low
$1.15
Volume
45,263
Avg. Vol
35,126
52-wk High
$3.89
52-wk Low
$0.90

Select another date:

Thu, Jan 4 2018

BRIEF-Eyegate Promotes Sarah Romano To CFO

* EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018 Source text for Eikon: Further company coverage:

BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment

* EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

* EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

BRIEF-Eyegate Pharmaceuticals Q2 revenue $148,000

* Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update

BRIEF-Eyegate Pharma enrolls first patient in phase 2b clinical study

* Eyegate Pharma enrolls first patient in phase 2b clinical study of EGP-437 for cataract surgery Source text for Eikon: Further company coverage:

Select another date: